Author

Li Yu

Institution: Syndax Pharmaceuticals (United States)

Observed institutions: Wuhan Union Hospital, Syndax Pharmaceuticals (United States), Huazhong University of Science and Technology

ORCID: 0009-0004-5925-5937

Observed ORCID: 0009-0004-5925-5937

OpenAlex ID: A5102927751

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

2025 · Ibrahim Aldoss, Ghayas Issa, et al. · Blood · 5

AML-112: Revumenib Activity in Patients With Acute Leukemia With NUP98r: Results From the AUGMENT-101 Phase 1 Study

2025 · Ghayas C. Issa, Branko Cuglievan, et al. · Clinical Lymphoma Myeloma & Leukemia · 4

AML-111: Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)

2025 · Ibrahim Aldoss, Ghayas C. Issa, et al. · Clinical Lymphoma Myeloma & Leukemia · 3

Fasting Blood Glucose-Based Novel Predictors in Detecting Metastases and Predicting Prognosis for Patients with PNENs

2024 · Li Yu, Mengfei Fu, et al. · Journal of Personalized Medicine · 3

POSTER: AML-111 Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL)

2025 · Ibrahim Aldoss, Ghayas C. Issa, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 5

Citation count: 15

H-index: 3

I10-index: